iiinova — where your digital self keeps evolving

Reposted by Sruthi Haridas

Nephrology Journal Club @nephjc.bsky.social · 06/05/2026

8/10 #NephJC Consensus 1️⃣BI 764198 administration in 1° FSGS caused a modest ⬇️UPCR 2️⃣Unclear if this will lead to better eGFR outcomes in a heterogenous group of FSGS pts 3️⃣Appears most helpful in genetic FSGS with TRPC6 mutations

122

Reposted by Sruthi Haridas

Nephrology Journal Club @nephjc.bsky.social · 06/05/2026

5/10 A figure paints🖼️ a 1000 words! This figure is… a lot. Full analysis & per protocol sets at various doses Small # in each group A) 1° endpoint: 25% ⬇️ UPCR from baseline D) Proportion achieving a UPCR of <1 g/g E) Δ in 24 h UPCR in pts with confirmed TRPC6

112

Reposted by Sruthi Haridas

Nephrology Journal Club @nephjc.bsky.social · 06/05/2026

4/10 One post results Of the 60 pts: 1° endpoint (≥ 25% ⬇️ in UPCR from baseline at week 12) was seen in 7% of placebo vs 35% of all BI 764198 dose groups OR 4.9 [95% CI 1.0–48.8]

112

Reposted by Sruthi Haridas

Nephrology Journal Club @nephjc.bsky.social · 06/05/2026

3/10 One post methods Phase 2, multicentric/multinational, parallel-group, placebo controlled RCT Primary FSGS or genetic FSGS resulting from a TRPC6 variant. Patients were given 20/40/80 mg of study drug

112

Reposted by Sruthi Haridas

Kidney International @kidneyint.bsky.social · 21/04/2026

N-propargylglycine restores survival by preventing calcium oxalate stone formation, tubular injury, and kidney dysfunction in a lethal mouse model of primary hyperoxaluria type 2 doi.org/10.1016/j.kint.2026.02.024 #MedSky #NephSky #OpenAccess

021

Reposted by Sruthi Haridas

UK Kidney Association @ukkidney.org · 16/04/2026

📢 The FDA has approved the first ever treatment for FSGS, supported by the PARASOL initiative. RaDaR contributed as an external validation cohort, highlighting the power of global collaboration & patient data. 📰: ow.ly/IJNH50YJXBB #RareDisease #KidneyResearch #FSGS

012

Sruthi Haridas @sruthiharidas.bsky.social · 31/03/2026

#NephMadness 2026 Really enjoyed this year’s writeups.. thoughtful and high-yield 👏 There’s a clear shift in nephrology: from broad immunosuppression → more targeted therapies. Still learning the ropes, but this was fun 🙂 Curious to see which direction the panel leans 👀 #NephMadnessNewbie

111

Reposted by Sruthi Haridas

NephMadness @nephmadness.bsky.social · 31/03/2026

⏰ Just a few hours left to submit your #NephMadness 2026 bracket! The fun of #NephMadness is making your prediction on which team will become the 2026 Champion. Already submitted one? Disagreed with the group? Submit a back-up bracket: bit.ly/2DvWyou

111

Reposted by Sruthi Haridas

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 29/03/2026

Also see this study from India in @kireports.bsky.social Is there somethung special about targeted release $$$ vs enteric coated $ budesonide? bsky.app/profile/hswa... #ISNWCN

252

Sruthi Haridas @sruthiharidas.bsky.social · 29/03/2026

Hi, I’m Sruthi, Nephrologist from Kerala, India. I’m into clinical medicine, research, and lately curious about AI. Outside work, I enjoy time with family, art, and real conversations. Here to learn, connect, and grow 🙂 #Nephsky #Nephbluesky #Medsky

051